Drugs / Exosomes overexpressing CD24
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04969172 Comparator | Jul 2021 → Jul 2022 | COVID-19 | Eli Sprecher, MD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Exosomes overexpressing CD24 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04969172 ↗ |
| Modality | Other / unclassified | “uses exosomes that were engineered to overexpress CD24” NCT04969172 ↗ |
| Route | Inhaled | “for inhalation, administered once daily (QD) for 5 days” NCT04969172 ↗ |